Advertisement
Screener

PUMA BIOTECHNOLOGY, INC. (PBYI) Net Income (Loss) Available to Common Stockholders, Basic

2.1 / 5 stars · 34/80 Roast Me

PUMA BIOTECHNOLOGY, INC. Net Income (Loss) Available to Common Stockholders, Basic

PUMA BIOTECHNOLOGY, INC. (PBYI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$14.99 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-01

  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$14.99M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$31.46M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was $3.40M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$16.93M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$59.99M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$75.59M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$113.58M.
  • PUMA BIOTECHNOLOGY, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$291.95M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 3 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 4 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 6 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 9 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 12 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 16 monthNet Income (Loss) Available to Common Stockholders, Basic 18 monthNet Income (Loss) Available to Common Stockholders, Basic 21 monthNet Income (Loss) Available to Common Stockholders, Basic 25 monthNet Income (Loss) Available to Common Stockholders, Basic 27 monthNet Income (Loss) Available to Common Stockholders, Basic 30 monthNet Income (Loss) Available to Common Stockholders, Basic 33 monthNet Income (Loss) Available to Common Stockholders, Basic 36 monthNet Income (Loss) Available to Common Stockholders, Basic 39 monthNet Income (Loss) Available to Common Stockholders, Basic 42 monthNet Income (Loss) Available to Common Stockholders, Basic 45 monthNet Income (Loss) Available to Common Stockholders, Basic 48 month
2020-12-31-$14.99M
10-K · filed 2021-03-01
-$46.46M
derived: sum of 2 quarters · filed 2021-03-01
-$43.06M
derived: sum of 3 quarters · filed 2021-03-01
-$59.99M
10-K · filed 2021-03-01
2020-09-30-$31.46M
10-K · filed 2021-03-01
-$28.07M
derived: sum of 2 quarters · filed 2021-03-01
-$45.00M
10-Q · filed 2020-11-05
-$56.20M
derived: sum of 4 quarters · filed 2021-03-01
2020-06-30$3.40M
10-K · filed 2021-03-01
-$13.54M
10-Q · filed 2020-08-06
-$24.74M
derived: sum of 3 quarters · filed 2021-03-01
-$41.62M
derived: sum of 4 quarters · filed 2021-03-01
2020-03-31-$16.93M
10-K · filed 2021-03-01
-$28.13M
derived: sum of 2 quarters · filed 2021-03-01
-$45.02M
derived: sum of 3 quarters · filed 2021-03-01
-$82.44M
derived: sum of 4 quarters · filed 2021-03-01
2019-12-31-$11.20M
10-K · filed 2021-03-01
-$28.08M
derived: sum of 2 quarters · filed 2021-03-01
-$65.51M
derived: sum of 3 quarters · filed 2021-03-01
-$75.59M
10-K · filed 2021-03-01
2019-09-30-$16.89M
10-K · filed 2021-03-01
-$54.31M
derived: sum of 2 quarters · filed 2021-03-01
-$64.40M
10-Q · filed 2020-11-05
-$95.09M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$37.42M
10-K · filed 2021-03-01
-$47.51M
10-Q · filed 2020-08-06
-$78.20M
derived: sum of 3 quarters · filed 2021-03-01
-$92.41M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$10.09M
10-K · filed 2021-03-01
-$40.78M
derived: sum of 2 quarters · filed 2021-03-01
-$54.98M
derived: sum of 3 quarters · filed 2021-03-01
-$99.32M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31-$30.69M
10-K · filed 2021-03-01
-$44.90M
derived: sum of 2 quarters · filed 2021-03-01
-$89.23M
derived: sum of 3 quarters · filed 2021-03-01
-$113.58M
10-K · filed 2021-03-01
2018-09-30-$14.20M
10-K · filed 2021-03-01
-$58.54M
derived: sum of 2 quarters · filed 2021-03-01
-$82.88M
10-Q · filed 2019-11-07
-$146.96M
derived: sum of 4 quarters · filed 2021-03-01
2018-06-30-$44.34M
10-K · filed 2021-03-01
-$68.68M
10-Q · filed 2019-08-09
-$132.76M
derived: sum of 3 quarters · filed 2021-03-01
-$209.94M
derived: sum of 4 quarters · filed 2021-03-01
2018-03-31-$24.34M
10-K · filed 2021-03-01
-$88.42M
derived: sum of 2 quarters · filed 2021-03-01
-$165.60M
derived: sum of 3 quarters · filed 2021-03-01
-$243.44M
derived: sum of 4 quarters · filed 2021-03-01
2017-12-31-$64.08M
10-K · filed 2020-02-28
$64.08M
10-K · filed 2018-03-09
-$141.26M
derived: sum of 2 quarters · filed 2020-02-28
-$219.09M
derived: sum of 3 quarters · filed 2020-02-28
-$291.95M
10-K · filed 2020-02-28
2017-09-30-$77.18M
10-K · filed 2020-02-28
-$155.01M
derived: sum of 2 quarters · filed 2020-02-28
-$227.88M
10-Q · filed 2018-11-05
-$300.54M
derived: sum of 4 quarters · filed 2020-02-28
2017-06-30-$77.83M
10-K · filed 2020-02-28
-$150.70M
10-Q · filed 2018-08-09
-$223.36M
derived: sum of 3 quarters · filed 2020-02-28
-$289.14M
derived: sum of 4 quarters · filed 2020-02-28
2017-03-31-$72.86M
10-K · filed 2020-02-28
-$145.53M
derived: sum of 2 quarters · filed 2020-02-28
-$211.31M
derived: sum of 3 quarters · filed 2020-02-28
-$277.90M
derived: sum of 4 quarters · filed 2020-02-28
2016-12-31-$72.66M
10-K · filed 2019-03-01
-$138.44M
derived: sum of 2 quarters · filed 2019-03-01
-$205.04M
derived: sum of 3 quarters · filed 2019-03-01
-$276.01M
10-K · filed 2019-03-01
2016-09-30-$65.78M
10-K · filed 2019-03-01
-$132.38M
derived: sum of 2 quarters · filed 2019-03-01
-$203.35M
10-Q · filed 2017-11-09
-$265.07M
derived: sum of 4 quarters · filed 2019-03-01
2016-06-30-$66.60M
10-K · filed 2019-03-01
-$137.57M
10-Q · filed 2017-08-09
-$199.29M
derived: sum of 3 quarters · filed 2019-03-01
-$259.70M
derived: sum of 4 quarters · filed 2019-03-01
2016-03-31-$70.97M
10-K · filed 2019-03-01
-$132.69M
derived: sum of 2 quarters · filed 2019-03-01
-$193.11M
derived: sum of 3 quarters · filed 2019-03-01
-$257.80M
derived: sum of 4 quarters · filed 2019-03-01
2015-12-31-$61.72M
10-K · filed 2018-03-09
-$122.14M
derived: sum of 2 quarters · filed 2018-03-09
-$186.83M
derived: sum of 3 quarters · filed 2018-03-09
-$239.28M
10-K · filed 2018-03-09
2015-09-30-$60.42M
10-K · filed 2018-03-09
-$125.11M
derived: sum of 2 quarters · filed 2018-03-09
-$177.56M
10-Q · filed 2016-11-09
-$225.05M
derived: sum of 4 quarters · filed 2018-03-09
2015-06-30-$64.69M
10-K · filed 2018-03-09
-$117.15M
10-Q · filed 2016-08-09
-$164.63M
derived: sum of 3 quarters · filed 2018-03-09
-$200.47M
derived: sum of 4 quarters · filed 2018-03-09
2015-03-31-$52.45M
10-K · filed 2018-03-09
-$99.94M
derived: sum of 2 quarters · filed 2018-03-09
-$135.78M
derived: sum of 3 quarters · filed 2018-03-09
-$174.63M
derived: sum of 4 quarters · filed 2018-03-09
2014-12-31-$47.48M
10-K · filed 2017-03-01
-$83.33M
derived: sum of 2 quarters · filed 2017-03-01
-$122.17M
derived: sum of 3 quarters · filed 2017-03-01
-$141.97M
10-K · filed 2017-03-01
2014-09-30-$35.84M
10-K · filed 2017-03-01
-$74.69M
derived: sum of 2 quarters · filed 2017-03-01
-$94.48M
10-Q · filed 2015-11-09
-$110.43M
derived: sum of 4 quarters · filed 2017-03-01
-$233.73M
10-Q · filed 2014-11-10
2014-06-30-$38.84M
10-K · filed 2017-03-01
-$58.64M
10-Q · filed 2015-08-10
-$74.58M
derived: sum of 3 quarters · filed 2017-03-01
-$88.87M
derived: sum of 4 quarters · filed 2017-03-01
-$197.89M
10-Q · filed 2014-08-11
2014-03-31-$19.79M
10-K · filed 2017-03-01
-$35.74M
derived: sum of 2 quarters · filed 2017-03-01
-$50.02M
derived: sum of 3 quarters · filed 2017-03-01
-$62.67M
derived: sum of 4 quarters · filed 2017-03-01
-$159.04M
10-Q · filed 2014-05-12
2013-12-31-$15.95M
10-K · filed 2016-02-29
-$30.23M
derived: sum of 2 quarters · filed 2016-02-29
-$42.88M
derived: sum of 3 quarters · filed 2016-02-29
-$54.66M
10-K · filed 2016-02-29
-$139.25M
10-K · filed 2014-03-03
2013-09-30-$14.28M
10-K · filed 2016-02-29
-$26.93M
derived: sum of 2 quarters · filed 2016-02-29
-$38.71M
10-Q · filed 2014-11-10
-$60.63M
derived: sum of 4 quarters · filed 2016-02-29
-$123.31M
10-Q · filed 2013-11-12
2013-06-30-$12.65M
10-K · filed 2016-02-29
-$24.43M
10-Q · filed 2014-08-11
-$46.34M
derived: sum of 3 quarters · filed 2016-02-29
-$72.20M
derived: sum of 4 quarters · filed 2016-02-29
-$109.02M
10-Q · filed 2013-08-06
2013-03-31-$11.78M
10-K · filed 2016-02-29
-$33.69M
derived: sum of 2 quarters · filed 2016-02-29
-$59.55M
derived: sum of 3 quarters · filed 2016-02-29
-$74.31M
derived: sum of 4 quarters · filed 2016-02-29
-$96.37M
10-Q · filed 2013-05-09
2012-12-31-$21.91M
10-K · filed 2015-03-02
-$47.77M
derived: sum of 2 quarters · filed 2015-03-02
-$62.53M
derived: sum of 3 quarters · filed 2015-03-02
-$74.35M
10-K · filed 2015-03-02
-$84.59M
10-K · filed 2013-04-01
2012-09-30-$25.86M
10-K · filed 2015-03-02
-$25.86M
10-Q · filed 2012-11-14
-$40.61M
derived: sum of 2 quarters · filed 2015-03-02
-$52.44M
10-Q · filed 2013-11-12
-$52.44M
10-Q · filed 2012-11-14
-$62.29M
derived: sum of 4 quarters · filed 2015-03-02
-$62.68M
10-Q · filed 2012-11-14
2012-06-30-$14.75M
10-K · filed 2015-03-02
-$14.75M
10-Q · filed 2012-08-14
-$26.58M
10-Q · filed 2013-08-06
-$26.58M
10-Q · filed 2012-08-14
-$36.43M
derived: sum of 3 quarters · filed 2015-03-02
-$36.77M
derived: sum of 4 quarters · filed 2015-03-02
-$36.82M
10-Q · filed 2012-08-14
2012-03-31-$11.83M
10-K · filed 2015-03-02
-$11.83M
10-Q · filed 2012-05-15
-$21.67M
derived: sum of 2 quarters · filed 2015-03-02
-$22.02M
derived: sum of 3 quarters · filed 2015-03-02
-$22.06M
derived: sum of 4 quarters · filed 2015-03-02
-$22.07M
10-Q · filed 2012-05-15
2011-12-31-$9.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$10.19M
derived: sum of 2 quarters · filed 2014-03-03
-$10.23M
derived: sum of 3 quarters · filed 2014-03-03
-$10.23M
10-K · filed 2014-03-03
-$10.23M
10-K · filed 2012-03-29
-$10.24M
10-K · filed 2012-03-29
2011-09-30-$347.43K
10-Q · filed 2012-11-14
-$381.70K
derived: sum of 2 quarters · filed 2012-11-14
-$385.64K
10-Q · filed 2012-11-14
-$392.57K
10-Q · filed 2011-11-14
2011-06-30-$34.27K
10-Q · filed 2012-08-14
-$38.21K
10-Q · filed 2012-08-14
-$45.21K
derived: sum of 3 quarters · filed 2013-04-01
-$51.84K
derived: sum of 4 quarters · filed 2013-04-01
2011-03-31-$3.94K
10-Q · filed 2012-05-15
-$10.94K
derived: sum of 2 quarters · filed 2013-04-01
-$17.57K
derived: sum of 3 quarters · filed 2013-04-01
2010-12-31-$7.00K
10-K · filed 2013-04-01
-$6.93K
10-K · filed 2012-03-29
-$13.63K
derived: sum of 2 quarters · filed 2013-04-01
2010-09-30-$6.63K
10-Q · filed 2011-11-14
-$6.63K
10-Q · filed 2011-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARVINAS, INC. (ARVN)United States$0.510B58.38
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Evolus, Inc. (EOLS)United States$0.519B-13.32
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76